InsidersTradesSigma
Track the BioArctic AB share price and the full directors' dealings record of the company, a listed issuer based in Finland. Shares are quoted on the FI market, under the authority of FIN-FSA. Operating in the Health Care sector, BioArctic AB has published 10 public disclosures. Market capitalisation: €27.1bn. The latest transaction was filed on 19 December 2025 (Sale). Among the most active insiders: Anna-Kaija Grönblad. All data is openly available.
10
Insider Decl.
n/a
Thresholds
€85,955
5 ops.
Buy Volume
€10m
5 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate BioArctic AB Hold (neutral), based on 5 analysts. Average price target: SEK 301.40.
32Σ signal
Fundamental score
Ranked 5,317 of 29,056 companies
67.8
score / 100
Value47
Quality88
FCF yld5.0%
Earn yld3.6%
EV/EBITDA22.4x
ROE10%
Gross mgn97%
Net mgn51%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 19 December 2025
Declarations10 total
173,750 shares@ €28.36530.018% mcap100.0% of flowAktieISIN SE0010323311FI:A003U936-1
173,750 shares@ €28.36530.018% mcap100.0% of flowAktieISIN SE0010323311FI:A003U935-1
500 shares@ €29.16640.0001% mcap100.0% of flowAktieISIN SE0010323311FI:A003U619-1
3,000 shares@ €27.25450.0003% mcap100.0% of flowAktieISIN SE0010323311FI:A003R872-2
10,000 shares@ €27.25450.0010% mcap100.0% of flowAktieISIN SE0010323311FI:A003R873-2
1,750 shares@ €17.72060.0001% mcap100.0% of flowAktieISIN SE0010323311FI:A003P335-1
198 shares@ €14.67120.0000% mcap100.0% of flowAktieISIN SE0010323311FI:A003N413-1
500 shares@ €14.8060.0000% mcap100.0% of flowAktieISIN SE0010323311FI:A003N411-1
2,422 shares@ €14.67120.0001% mcap100.0% of flowAktieISIN SE0010323311FI:A003N415-2
448 shares@ €20.31820.0000% mcap100.0% of flowAktieISIN SE0010323311FI:A003M358-1
10 of 10 declarations
About BioArctic AB
BioArctic AB is a Swedish biopharmaceutical company focused on developing treatments for neurodegenerative diseases. It is listed on the Stockholm Stock Exchange under the symbol XSTO.